Compare iShares Core High Dividend ETF (HDV) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs Mesoblast Limited — how do they compare? iShares Core High Dividend ETF trades at $28.78 (market cap $14.72B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: iShares Core High Dividend ETF is far larger — about 8.1× Mesoblast Limited's market cap, and iShares Core High Dividend ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and Mesoblast Limited for 14 Days on average.
| HDV | MESO | |
|---|---|---|
Market Cap | $14.72B | $1.81B |
Volume | 2,297,177 | 240,620 |
52-Week High | $29.93 | $20.96 |
52-Week Low | $23.64 | $13.19 |
Typical Hold Time | 117 Days | 14 Days |
Sector | — | Health |
Enterprise Value | — | $1.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.28, down 0.28% with neutral technical signals. The ETF recently underwent significant sector rebalancing, reducing healthcare exposure by nearly half while increasing energy, staples, and utilities. Technical indicators show mixed signals with bearish moving averages but neutral oscillators. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation, though the fund's 3% yield may not fully compensate for increased concentration risks.
The outlook remains cautious as HDV's sector concentration (62% in three sectors) creates heightened risk exposure. While the dividend yield provides income stability, the fund's recent underperformance relative to peers and reduced diversification warrant careful monitoring. Investors should weigh the trade-off between current income and long-term growth potential given the significant portfolio restructuring.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
